Home LiteratureArticle Details
PMID: 24212610 Published · epublish English Journal Article

Decoding melanoma metastasis.

Cancers ·Vol. 3 ·No. 1 ·2010-12-30 ·Pages 126-63

Damsky WE, Rosenbaum LE, Bosenberg M

Abstract

Metastasis accounts for the vast majority of morbidity and mortality associated with melanoma. Evidence suggests melanoma has a predilection for metastasis to particular organs. Experimental analyses have begun to shed light on the mechanisms regulating melanoma metastasis and organ specificity, but these analyses are complicated by observations of metastatic dormancy and dissemination of melanocytes that are not yet fully malignant. Additionally, tumor extrinsic factors in the microenvironment, both at the site of the primary tumor and the site of metastasis, play important roles in mediating the metastatic process. As metastasis research moves forward, paradigms explaining melanoma metastasis as a step-wise process must also reflect the temporal complexity and heterogeneity in progression of this disease. Genetic drivers of melanoma as well as extrinsic regulators of disease spread, particularly those that mediate metastasis to specific organs, must also be incorporated into newer models of melanoma metastasis.

Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Damsky William E
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. marcus.bosenberg@yale.edu.
Rosenbaum Lara E
Bosenberg Marcus
References (255)
255 references, click to expand
  1. Brain metastasis: role of trophic, autocrine, and paracrine factors in tumor invasion and colonization of the central nervous system.
    Curr Top Microbiol Immunol. 1996;213 ( Pt 2):89-115 PMID: 9053298
  2. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.
    Clin Cancer Res. 2008 Feb 1;14(3):638-45 PMID: 18245522
  3. Fas and Fas ligand interactions suppress melanoma lung metastasis.
    J Exp Med. 1998 Nov 2;188(9):1717-23 PMID: 9802983
  4. Selection of successive tumour lines for metastasis.
    Nat New Biol. 1973 Apr 4;242(118):148-9 PMID: 4512654
  5. The Catalogue of Somatic Mutations in Cancer (COSMIC).
    Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11 PMID: 18428421
  6. The role of trophic factors and autocrine/paracrine growth factors in brain metastasis.
    Clin Exp Metastasis. 1995 Mar;13(2):67-88 PMID: 7882617
  7. Cancer statistics, 1996.
    CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 PMID: 8548526
  8. Metastatic malignant melanoma with an unknown primary.
    Surg Gynecol Obstet. 1983 Mar;156(3):335-40 PMID: 6828979
  9. Modulation of prostate cancer growth in bone microenvironments.
    J Cell Biochem. 2004 Mar 1;91(4):686-705 PMID: 14991761
  10. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.
    Nature. 2007 Oct 11;449(7163):682-8 PMID: 17898713
  11. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells.
    Mol Med. 2002 Aug;8(8):451-61 PMID: 12435856
  12. Molecular mechanisms of metastasis.
    Cancer Metastasis Rev. 2006 Jun;25(2):203-20 PMID: 16770533
  13. The current causes of death in patients with malignant melanoma.
    Eur J Cancer. 1978 Apr;14(4):327-30 PMID: 648555
  14. The epithelial-mesenchymal transition generates cells with properties of stem cells.
    Cell. 2008 May 16;133(4):704-15 PMID: 18485877
  15. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1.
    Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9 PMID: 10639148
  16. Efficient tumour formation by single human melanoma cells.
    Nature. 2008 Dec 4;456(7222):593-8 PMID: 19052619
  17. Adaptive immunity maintains occult cancer in an equilibrium state.
    Nature. 2007 Dec 6;450(7171):903-7 PMID: 18026089
  18. Real-time imaging reveals the single steps of brain metastasis formation.
    Nat Med. 2010 Jan;16(1):116-22 PMID: 20023634
  19. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes.
    Ann Surg Oncol. 1999 Apr-May;6(3):232-40 PMID: 10340881
  20. Early tumor dissemination, but late metastasis: insights into tumor dormancy.
    J Clin Invest. 2010 Jun;120(6):1800-3 PMID: 20501952
  21. Prognostic factors in 1,521 melanoma patients with distant metastases.
    J Am Coll Surg. 1995 Sep;181(3):193-201 PMID: 7670677
  22. Metastasis mechanisms.
    Biochim Biophys Acta. 2009 Dec;1796(2):293-308 PMID: 19683560
  23. Single-cell tumor dormancy model of uveal melanoma.
    Clin Exp Metastasis. 2008;25(5):509-16 PMID: 18335317
  24. Characterization of melanoma cells capable of propagating tumors from a single cell.
    Cancer Res. 2010 Jan 1;70(1):388-97 PMID: 20048081
  25. Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation.
    Melanoma Res. 2010 Oct;20(5):361-71 PMID: 20679910
  26. Organ targeting in vivo using phage display peptide libraries.
    Nature. 1996 Mar 28;380(6572):364-6 PMID: 8598934
  27. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation.
    Nat Genet. 2005 Oct;37(10):1047-54 PMID: 16142232
  28. The annual risk of melanoma progression. Implications for the concept of cure.
    Cancer. 1992 Oct 1;70(7):1917-27 PMID: 1525767
  29. BRAF signaling and targeted therapies in melanoma.
    Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix PMID: 19464601
  30. Integrative genome comparison of primary and metastatic melanomas.
    PLoS One. 2010 May 24;5(5):e10770 PMID: 20520718
  31. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.
    Cancer Res. 2008 Nov 15;68(22):9451-8 PMID: 19010920
  32. Pathogenesis of benign metastasizing leiomyoma: a review.
    Obstet Gynecol Surv. 2010 Mar;65(3):189-95 PMID: 20214834
  33. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes.
    Exp Clin Immunogenet. 1998;15(1):19-32 PMID: 9619397
  34. Experimental frontiers for clinical applications: novel approaches to understanding mechanisms of lymph node metastases in melanoma.
    Cancer Metastasis Rev. 2006 Jun;25(2):257-67 PMID: 16770538
  35. Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma.
    Australas J Dermatol. 1990;31(2):77-80 PMID: 2095738
  36. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine.
    J Natl Cancer Inst. 1970 Oct;45(4):773-82 PMID: 5513503
  37. Ultra-late recurrence (15 years or longer) of cutaneous melanoma.
    Cancer. 1997 Jun 15;79(12):2361-70 PMID: 9191524
  38. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  39. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.
    Cancer Res. 2002 Dec 15;62(24):7328-34 PMID: 12499276
  40. Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential.
    Am J Pathol. 2006 Sep;169(3):1064-73 PMID: 16936278
  41. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment.
    Mod Pathol. 2001 Jun;14(6):604-8 PMID: 11406663
  42. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858.
    Nutr Rev. 1989 Jan;47(1):23-5 PMID: 2649802
  43. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?
    Clin Exp Metastasis. 2010 Aug;27(6):371-87 PMID: 20177751
  44. LDH and melanoma.
    Cancer. 1983 Mar 1;51(5):840-3 PMID: 6821850
  45. Locoregional cutaneous metastases of malignant melanoma and their management.
    Dermatol Surg. 2004 Feb;30(2 Pt 2):244-7 PMID: 14871216
  46. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy.
    Ann Surg Oncol. 2010 Feb;17(2):514-20 PMID: 19924486
  47. Immune evasion by murine melanoma mediated through CC chemokine receptor-10.
    J Exp Med. 2003 Nov 3;198(9):1337-47 PMID: 14581607
  48. Cancer micrometastases.
    Nat Rev Clin Oncol. 2009 Jun;6(6):339-51 PMID: 19399023
  49. The basics of epithelial-mesenchymal transition.
    J Clin Invest. 2009 Jun;119(6):1420-8 PMID: 19487818
  50. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase.
    Ann Surg Oncol. 2000 May;7(4):262-7 PMID: 10819365
  51. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1.
    Science. 2008 Aug 22;321(5892):1095-100 PMID: 18719287
  52. Genes that mediate breast cancer metastasis to lung.
    Nature. 2005 Jul 28;436(7050):518-24 PMID: 16049480
  53. Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanoma.
    Surg Gynecol Obstet. 1990 Nov;171(5):393-7 PMID: 2237723
  54. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma.
    Cancer Res. 1975 Mar;35(3):512-6 PMID: 1090362
  55. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases.
    Arch Dermatol. 1998 Aug;134(8):991-4 PMID: 9722729
  56. Benign lymph node inclusions mimicking metastatic carcinoma.
    J Clin Pathol. 1994 Mar;47(3):245-7 PMID: 8163697
  57. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate.
    Arch Dermatol. 2003 Mar;139(3):282-8 PMID: 12622618
  58. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    J Natl Cancer Inst. 2006 Apr 5;98(7):472-82 PMID: 16595783
  59. Cancer micrometastasis and tumour dormancy.
    APMIS. 2008 Jul-Aug;116(7-8):754-70 PMID: 18834417
  60. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update.
    Transplantation. 2007 Jul 27;84(2):272-4 PMID: 17667822
  61. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency.
    Cancer Res. 2000 May 1;60(9):2541-6 PMID: 10811137
  62. Do metastases metastasize?
    J Pathol. 2004 May;203(1):515-8 PMID: 15095473
  63. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice.
    J Natl Cancer Inst. 1984 Apr;72(4):913-7 PMID: 6584666
  64. Metastatic patterns in adenocarcinoma.
    Cancer. 2006 Apr 1;106(7):1624-33 PMID: 16518827
  65. A comprehensive catalogue of somatic mutations from a human cancer genome.
    Nature. 2010 Jan 14;463(7278):191-6 PMID: 20016485
  66. High frequency of BRAF mutations in nevi.
    Nat Genet. 2003 Jan;33(1):19-20 PMID: 12447372
  67. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma.
    Cancer Res. 1980 Jul;40(7):2281-7 PMID: 7388794
  68. The biology of melanoma brain metastasis.
    Cancer Metastasis Rev. 1999;18(3):387-400 PMID: 10721492
  69. The WNT/Beta-catenin pathway in melanoma.
    Front Biosci. 2006 Jan 01;11:733-42 PMID: 16146765
  70. Neurotrophin stimulation of human melanoma cell invasion: selected enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations.
    Cancer Res. 1996 Jun 15;56(12):2856-63 PMID: 8665526
  71. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.
    Cell Cycle. 2006 Aug;5(16):1779-87 PMID: 16931911
  72. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond.
    Cancer Metastasis Rev. 2006 Dec;25(4):521-9 PMID: 17186383
  73. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.
    Am J Clin Pathol. 2004 Jan;121(1):58-63 PMID: 14750241
  74. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases.
    J Immunol. 2008 Jan 1;180(1):130-7 PMID: 18097012
  75. Late recurrence of malignant melanoma. Analysis of 168 patients.
    Ann Surg. 1990 Aug;212(2):173-7 PMID: 2375648
  76. Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain.
    Cancer Res. 2009 Feb 1;69(3):828-35 PMID: 19141644
  77. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
    Clin Cancer Res. 2010 Jul 1;16(13):3356-67 PMID: 20460471
  78. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review.
    Am J Clin Pathol. 1994 Jul;102(1):102-8 PMID: 8037154
  79. Clinical aspects of unknown primary melanoma.
    Ann Surg. 1980 Jan;191(1):98-104 PMID: 7352784
  80. Diagnosis and staging of lymph node metastasis.
    Recent Results Cancer Res. 2000;157:20-8 PMID: 10857159
  81. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth.
    Cell Res. 2008 May;18(5):549-57 PMID: 18379589
  82. Cancer stem cells: models and concepts.
    Annu Rev Med. 2007;58:267-84 PMID: 17002552
  83. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape.
    Eur J Cancer. 2006 May;42(8):1181-7 PMID: 16644201
  84. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma.
    Cancer. 2001 Aug 1;92(3):535-41 PMID: 11505397
  85. Molecular pathways mediating liver metastasis in patients with uveal melanoma.
    Clin Cancer Res. 2008 Feb 15;14(4):951-6 PMID: 18281525
  86. Patterned distribution of metastases from malignant melanoma in humans.
    Cancer Res. 1983 Jul;43(7):3427-33 PMID: 6850649
  87. Oncogene-induced cellular senescence.
    Adv Anat Pathol. 2010 Jan;17(1):42-8 PMID: 20032638
  88. Role of angiogenesis in tumor growth and metastasis.
    Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 PMID: 12516034
  89. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study.
    Eye (Lond). 2007 Jun;21(6):752-9 PMID: 16575415
  90. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR.
    Oncogene. 2005 Sep 1;24(38):5897-904 PMID: 16007209
  91. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.
    Cancer Res. 2011 Jan 1;71(1):175-84 PMID: 21084275
  92. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
    Ann Surg Oncol. 2006 Jun;13(6):809-16 PMID: 16604476
  93. Evidence for the clonal origin of spontaneous metastases.
    Science. 1982 Jul 23;217(4557):361-3 PMID: 6953592
  94. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma.
    Am J Surg Pathol. 2000 Aug;24(8):1140-6 PMID: 10935655
  95. Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell.
    Cancer Res. 1986 Oct;46(10):5167-71 PMID: 3756870
  96. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases.
    Am J Surg. 1978 Jun;135(6):807-10 PMID: 665907
  97. Reprogramming metastatic tumour cells with embryonic microenvironments.
    Nat Rev Cancer. 2007 Apr;7(4):246-55 PMID: 17384580
  98. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis.
    J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):773-80 PMID: 2808793
  99. Endothelial cell membrane vesicles in the study of organ preference of metastasis.
    Cancer Res. 1991 Jan 1;51(1):394-9 PMID: 1988100
  100. Brain metastases in melanoma: roles of neurotrophins.
    Neuro Oncol. 2004 Apr;6(2):154-65 PMID: 15134630
  101. Liver metastasis formation by laminin-1 peptide (LQVQLSIR)-adhesion selected B16-F10 melanoma cells.
    Int J Cancer. 1997 May 2;71(3):436-41 PMID: 9139881
  102. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.
    J Neurosurg. 1998 Jan;88(1):11-20 PMID: 9420067
  103. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells.
    Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14470-5 PMID: 10588729
  104. MALIGNANT MELANOMA OF UNKNOWN PRIMARY ORIGIN.
    Surg Gynecol Obstet. 1963 Sep;117:341-5 PMID: 14080349
  105. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
    J Clin Oncol. 1983 Feb;1(2):126-34 PMID: 6668496
  106. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs.
    Am J Pathol. 2009 Feb;174(2):602-12 PMID: 19147814
  107. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
    Am J Surg Pathol. 2009 Apr;33(4):568-71 PMID: 19033861
  108. The chemokine and chemokine receptor superfamilies and their molecular evolution.
    Genome Biol. 2006;7(12):243 PMID: 17201934
  109. Organ selectivity in metastasis: regulation by chemokines and their receptors.
    Clin Exp Metastasis. 2008;25(4):345-56 PMID: 17891505
  110. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria.
    Eur J Cancer. 2010 Sep;46(13):2414-21 PMID: 20621467
  111. Chemokine-chemokine receptor axes in melanoma brain metastasis.
    Immunol Lett. 2010 May 4;130(1-2):107-14 PMID: 20005902
  112. Lymphocyte subset alterations in nodes regional to human melanoma.
    Cancer Res. 1990 Jun 15;50(12):3585-8 PMID: 1692763
  113. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment.
    Ophthalmology. 2000 Aug;107(8):1443-9 PMID: 10919885
  114. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.
    J Clin Invest. 2010 Jun;120(6):2030-9 PMID: 20501944
  115. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium.
    Cancer Res. 2003 Jan 15;63(2):491-7 PMID: 12543807
  116. The distribution of secondary growths in cancer of the breast. 1889.
    Cancer Metastasis Rev. 1989 Aug;8(2):98-101 PMID: 2673568
  117. How to make a melanoma: what do we know of the primary clonal events?
    Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38 PMID: 18353141
  118. Molecular classification of cutaneous malignant melanoma by gene expression profiling.
    Nature. 2000 Aug 3;406(6795):536-40 PMID: 10952317
  119. Organ-specificity of the extravasation process: an ultrastructural study.
    Clin Exp Metastasis. 2000;18(6):481-92 PMID: 11592305
  120. Cutaneous melanomas associated with nevi.
    Arch Dermatol. 2003 Dec;139(12):1620-4; discussion 1624 PMID: 14676081
  121. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.
    Hum Pathol. 1984 Dec;15(12):1147-65 PMID: 6500548
  122. Nodal nevi and cutaneous melanomas.
    Am J Surg Pathol. 1996 Jul;20(7):834-40 PMID: 8669531
  123. Microenvironmental influences in melanoma progression.
    J Cell Biochem. 2007 Jul 1;101(4):862-72 PMID: 17171636
  124. Role of tumor cell adhesion and migration in organ-specific metastasis formation.
    Onkologie. 2004 Dec;27(6):577-82 PMID: 15591720
  125. Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis.
    Oncogene. 2007 May 10;26(21):2997-3005 PMID: 17130836
  126. Main roads to melanoma.
    J Transl Med. 2009 Oct 14;7:86 PMID: 19828018
  127. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells.
    Immunology. 2005 Jul;115(3):325-36 PMID: 15946250
  128. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Melanoma Res. 2006 Dec;16(6):471-8 PMID: 17119447
  129. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms.
    Cancer Res. 2008 Apr 15;68(8):2745-54 PMID: 18417445
  130. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial.
    Ann Surg. 1993 Sep;218(3):262-7; discussion 267-9 PMID: 8373269
  131. Tumour dormancy: findings and hypotheses from clinical research on breast cancer.
    Semin Cancer Biol. 2001 Aug;11(4):297-306 PMID: 11513565
  132. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.
    Nature. 2010 Jul 1;466(7302):133-7 PMID: 20596026
  133. Identification of cells initiating human melanomas.
    Nature. 2008 Jan 17;451(7176):345-9 PMID: 18202660
  134. Seeding and propagation of untransformed mouse mammary cells in the lung.
    Science. 2008 Sep 26;321(5897):1841-4 PMID: 18755941
  135. Mutations of the BRAF gene in human cancer.
    Nature. 2002 Jun 27;417(6892):949-54 PMID: 12068308
  136. Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production.
    Int J Cancer. 1993 Oct 21;55(4):692-9 PMID: 8407001
  137. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
    Nature. 2005 Dec 8;438(7069):820-7 PMID: 16341007
  138. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes.
    Ann Surg. 2008 Dec;248(6):949-55 PMID: 19092339
  139. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
    Cancer Res. 2006 Aug 15;66(16):8200-9 PMID: 16912199
  140. Increased incidence of melanoma in renal transplantation recipients.
    Cancer. 2005 Nov 1;104(9):1962-7 PMID: 16187269
  141. Recent progress in understanding the pathology of malignant melanoma.
    J Pathol. 2009 Dec;219(4):400-9 PMID: 19771562
  142. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
    Am J Pathol. 2000 Oct;157(4):1123-8 PMID: 11021816
  143. Malignant melanoma: genetics and therapeutics in the genomic era.
    Genes Dev. 2006 Aug 15;20(16):2149-82 PMID: 16912270
  144. The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
    BMC Cancer. 2006 Mar 09;6:56 PMID: 16524486
  145. The bone marrow vascular niche: home of HSC differentiation and mobilization.
    Physiology (Bethesda). 2005 Oct;20:349-56 PMID: 16174874
  146. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1.
    Exp Cell Res. 2002 Feb 15;273(2):229-39 PMID: 11822878
  147. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma.
    J Natl Cancer Inst. 2001 Nov 7;93(21):1638-43 PMID: 11698568
  148. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.
    Cancer Cell. 2010 Nov 16;18(5):510-23 PMID: 21075313
  149. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience.
    Cancer. 1984 Jun 1;53(11):2550-2 PMID: 6713349
  150. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.
    Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9023-8 PMID: 16757564
  151. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.
    Cancer Metastasis Rev. 1988 Jun;7(2):143-88 PMID: 3293836
  152. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells.
    Clin Cancer Res. 2004 Apr 1;10(7):2351-8 PMID: 15073111
  153. Epithelial-mesenchymal transition and cell cooperativity in metastasis.
    Cancer Res. 2009 Sep 15;69(18):7135-9 PMID: 19738043
  154. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display.
    J Clin Invest. 1998 Jul 15;102(2):430-7 PMID: 9664085
  155. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.
    Nat Med. 1995 Feb;1(2):149-53 PMID: 7585012
  156. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
    J Invest Dermatol. 2005 Aug;125(2):312-7 PMID: 16098042
  157. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
    Oncogene. 2010 Nov 25;29(47):6222-32 PMID: 20711233
  158. Genomic instability and cancer.
    Curr Mol Med. 2003 Nov;3(7):589-96 PMID: 14601634
  159. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro.
    J Cell Sci. 1994 Apr;107 ( Pt 4):983-92 PMID: 8056851
  160. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
    Cell. 2010 May 14;141(4):583-94 PMID: 20478252
  161. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.
    J Clin Oncol. 2004 Sep 15;22(18):3668-76 PMID: 15302909
  162. Skeletal metastases of melanoma: radiographic, scintigraphic, and clinical review.
    AJR Am J Roentgenol. 1981 Jul;137(1):103-8 PMID: 6787858
  163. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
    Cancer. 1982 Oct 15;50(8):1656-63 PMID: 7116298
  164. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.
    Am J Pathol. 1999 Feb;154(2):325-9 PMID: 10027390
  165. Integrins: bidirectional, allosteric signaling machines.
    Cell. 2002 Sep 20;110(6):673-87 PMID: 12297042
  166. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
    J Clin Oncol. 2001 Aug 15;19(16):3622-34 PMID: 11504744
  167. Metastasis results from preexisting variant cells within a malignant tumor.
    Science. 1977 Aug 26;197(4306):893-5 PMID: 887927
  168. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.
    Cancer Cell. 2002 Jun;1(5):445-57 PMID: 12124174
  169. The fallacy of epithelial mesenchymal transition in neoplasia.
    Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 PMID: 16024596
  170. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor.
    Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9 PMID: 19188590
  171. Melanoma.
    N Engl J Med. 2006 Jul 6;355(1):51-65 PMID: 16822996
  172. Lymphatic endothelium: a new frontier of metastasis research.
    Nat Cell Biol. 2002 Jan;4(1):E2-5 PMID: 11780131
  173. Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis.
    Arch Dermatol. 2010 Oct;146(10):1120-4 PMID: 20956643
  174. Malignant melanoma: pattern of metastasis.
    CA Cancer J Clin. 1980 May-Jun;30(3):137-42 PMID: 6769552
  175. Metastasis: from dissemination to organ-specific colonization.
    Nat Rev Cancer. 2009 Apr;9(4):274-84 PMID: 19308067
  176. Activation of stat3 in human melanoma promotes brain metastasis.
    Cancer Res. 2006 Mar 15;66(6):3188-96 PMID: 16540670
  177. The good and the bad of chemokines/chemokine receptors in melanoma.
    Pigment Cell Melanoma Res. 2009 Apr;22(2):175-86 PMID: 19222802
  178. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.
    Am J Pathol. 1998 Sep;153(3):865-73 PMID: 9736035
  179. Chemokine receptors and melanoma metastasis.
    J Dermatol Sci. 2004 Nov;36(2):71-8 PMID: 15519136
  180. Analysis of 945 cases of pulmonary metastatic melanoma.
    J Thorac Cardiovasc Surg. 1992 Apr;103(4):743-8; discussion 748-50 PMID: 1548916
  181. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?
    Ann Surg Oncol. 2000 Mar;7(2):114-9 PMID: 10761789
  182. Cellular origin and developmental mechanisms during the formation of skin melanocytes.
    Exp Cell Res. 2010 May 1;316(8):1397-407 PMID: 20211169
  183. Immunotherapy for melanoma: current status and perspectives.
    J Immunother. 2010 Jul-Aug;33(6):570-90 PMID: 20551839
  184. Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.
    Am J Clin Oncol. 2010 Aug;33(4):398-407 PMID: 19675447
  185. Epithelium-mesenchyme transition during neural crest development.
    Acta Anat (Basel). 1995;154(1):63-78 PMID: 8714290
  186. Chronic alcohol consumption decreases the percentage and number of NK cells in the peripheral lymph nodes and exacerbates B16BL6 melanoma metastasis into the draining lymph nodes.
    Cell Immunol. 2011;266(2):172-9 PMID: 20974468
  187. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis.
    J Biol Chem. 2001 Jul 6;276(27):25438-46 PMID: 11320086
  188. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin.
    Cancer Res. 2003 Oct 15;63(20):6751-7 PMID: 14583470
  189. Paradoxical roles of the immune system during cancer development.
    Nat Rev Cancer. 2006 Jan;6(1):24-37 PMID: 16397525
  190. Inflammation and melanoma metastasis.
    Pigment Cell Melanoma Res. 2009 Jun;22(3):257-67 PMID: 19368690
  191. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines.
    Cancer Res. 2008 Mar 1;68(5):1362-8 PMID: 18316599
  192. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
    Science. 1997 May 30;276(5317):1423-5 PMID: 9162011
  193. Stem cells, cancer, and cancer stem cells.
    Nature. 2001 Nov 1;414(6859):105-11 PMID: 11689955
  194. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.
    J Clin Invest. 2001 Aug;108(3):341-7 PMID: 11489924
  195. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.
    J Clin Endocrinol Metab. 2010 Sep;95(9):4197-205 PMID: 20631031
  196. Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes.
    Mod Pathol. 2003 Sep;16(9):920-9 PMID: 13679456
  197. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma.
    Br J Dermatol. 2007 Dec;157(6):1212-6 PMID: 17970806
  198. Genes that mediate breast cancer metastasis to the brain.
    Nature. 2009 Jun 18;459(7249):1005-9 PMID: 19421193
  199. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study.
    Surg Gynecol Obstet. 1988 Jun;166(6):497-502 PMID: 3375961
  200. The biology of metastasis to a sanctuary site.
    Clin Cancer Res. 2007 Mar 15;13(6):1656-62 PMID: 17363518
  201. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  202. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes.
    Cancer Res. 2004 Jun 1;64(11):4010-7 PMID: 15173015
  203. Host and tumour factors in cancer metastasis.
    Eur J Clin Invest. 1990 Oct;20(5):481-6 PMID: 2124977
  204. A multigenic program mediating breast cancer metastasis to bone.
    Cancer Cell. 2003 Jun;3(6):537-49 PMID: 12842083
  205. MicroRNAs in Cancer.
    Annu Rev Med. 2009;60:167-79 PMID: 19630570
  206. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?
    Cell Cycle. 2006 Apr;5(8):812-7 PMID: 16627996
  207. Epigenetic silencing of the PTEN gene in melanoma.
    Cancer Res. 2006 Jul 1;66(13):6546-52 PMID: 16818626
  208. Malignant melanoma: prevention, early detection, and treatment in the 21st century.
    CA Cancer J Clin. 2000 Jul-Aug;50(4):215-36; quiz 237-40 PMID: 10986965
  209. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
    Nature. 2005 Jul 7;436(7047):117-22 PMID: 16001072
  210. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Melanoma Res. 2006 Aug;16(4):267-73 PMID: 16845322
  211. Dormancy of metastatic melanoma.
    Pigment Cell Melanoma Res. 2010 Feb;23(1):41-56 PMID: 19843243
  212. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.
    Clin Exp Metastasis. 2008;25(3):201-11 PMID: 18071913
  213. Naevus cells in lymph nodes.
    Pathology. 1974 Oct;6(4):351-8 PMID: 4449672
  214. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.
    Oncogene. 1998 Jul 2;16(26):3397-402 PMID: 9692547
  215. AACR centennial series: the biology of cancer metastasis: historical perspective.
    Cancer Res. 2010 Jul 15;70(14):5649-69 PMID: 20610625
  216. A population-based study of skin cancer incidence and prevalence in renal transplant recipients.
    Br J Dermatol. 2006 Mar;154(3):498-504 PMID: 16445782
  217. Frequent mutation of BAP1 in metastasizing uveal melanomas.
    Science. 2010 Dec 3;330(6009):1410-3 PMID: 21051595
  218. Skeletal metastases of melanoma.
    J Bone Joint Surg Am. 1978 Jul;60(5):645-9 PMID: 681383
  219. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
    Cell. 2009 Jul 10;138(1):51-62 PMID: 19576624
  220. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.
    Ann Surg. 2006 Jul;244(1):113-20 PMID: 16794396
  221. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.
    Clin Cancer Res. 2008 Aug 1;14(15):4735-42 PMID: 18676742
  222. Predicting clinical outcome through molecular profiling in stage III melanoma.
    Clin Cancer Res. 2008 Aug 15;14(16):5173-80 PMID: 18698035
  223. Risk factors for nodal recurrence after lymphadenectomy for melanoma.
    Ann Surg Oncol. 2001 Mar;8(2):109-15 PMID: 11258774
  224. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene.
    Cell. 2006 Jun 30;125(7):1269-81 PMID: 16814714
  225. Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway.
    Development. 1995 Mar;121(3):731-42 PMID: 7536655
  226. Final version of 2009 AJCC melanoma staging and classification.
    J Clin Oncol. 2009 Dec 20;27(36):6199-206 PMID: 19917835
  227. Characteristics associated with early and late melanoma metastases.
    Cancer. 2010 Jan 15;116(2):415-23 PMID: 19918926
  228. Mechanisms of motility in metastasizing cells.
    Mol Cancer Res. 2010 May;8(5):629-42 PMID: 20460404
  229. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo.
    World J Gastroenterol. 2006 Sep 14;12(34):5429-39 PMID: 17006978
  230. Involvement of chemokine receptors in breast cancer metastasis.
    Nature. 2001 Mar 1;410(6824):50-6 PMID: 11242036
  231. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
    Cancer Res. 1997 Sep 1;57(17):3660-3 PMID: 9288767
  232. Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner.
    Clin Exp Metastasis. 2008;25(1):11-32 PMID: 17828597
  233. Integrins: versatile receptors controlling melanocyte adhesion, migration and proliferation.
    Pigment Cell Melanoma Res. 2011 Apr;24(2):282-94 PMID: 21087420
  234. Insights into the mechanisms of lymph node metastasis.
    Cancer. 2003 Jul 15;98(2):413-23 PMID: 12872364
  235. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy.
    Ann Surg Oncol. 2001 Dec;8(10):766-70 PMID: 11776489
  236. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.
    Cancer Metastasis Rev. 2010 Jun;29(2):309-16 PMID: 20405169
  237. Dissecting the metastatic cascade.
    Nat Rev Cancer. 2004 Jun;4(6):448-56 PMID: 15170447
  238. Skeletal muscle phenotypically converts and selectively inhibits metastatic cells in mice.
    PLoS One. 2010 Feb 18;5(2):e9299 PMID: 20174581
  239. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy.
    J Natl Cancer Inst. 2007 Feb 21;99(4):309-21 PMID: 17312308
  240. Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells.
    J Cell Biochem. 2010 Dec 1;111(5):1299-309 PMID: 20803552
  241. The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest.
    J Biol Chem. 2007 Aug 17;282(33):24471-6 PMID: 17553787
  242. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
    PLoS One. 2007 Feb 21;2(2):e236 PMID: 17311103
  243. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.
    Am J Pathol. 2003 Jun;162(6):1951-60 PMID: 12759251
  244. A new era: melanoma genetics and therapeutics.
    J Pathol. 2011 Jan;223(2):241-50 PMID: 21125678
  245. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance.
    Cancer. 1977 Jan;39(1):164-71 PMID: 832230
  246. Wnt signalling required for expansion of neural crest and CNS progenitors.
    Nature. 1997 Oct 30;389(6654):966-70 PMID: 9353119
  247. Lineage-specific requirements of beta-catenin in neural crest development.
    J Cell Biol. 2002 Dec 9;159(5):867-80 PMID: 12473692
  248. Transmission of donor melanoma by organ transplantation.
    Lancet Oncol. 2010 Aug;11(8):790-6 PMID: 20451456
  249. Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule.
    Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9568-72 PMID: 1946371
  250. METASTATIC MELANOMA. A CLINICOPATHOLOGICAL STUDY.
    Cancer. 1964 Oct;17:1323-39 PMID: 14236766
  251. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
    Clin Cancer Res. 2007 Feb 15;13(4):1171-8 PMID: 17317826
  252. Mouse melanoma models and cell lines.
    Pigment Cell Melanoma Res. 2010 Dec;23(6):853-9 PMID: 20973935
  253. Experimental evidence in support of the dormant tumor cell.
    Science. 1959 Oct 9;130(3380):918-9 PMID: 13823184
  254. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    Nat Genet. 2009 May;41(5):544-52 PMID: 19282848
  255. Benign nevus cells in the capsule of lymph nodes.
    Cancer. 1969 Mar;23(3):747-53 PMID: 5766512
Article Info
Journal
Cancers
Abbr.
Cancers (Basel)
ISSN
2072-6694
DOI
10.3390/cancers3010126
Email
marcus.bosenberg@yale.edu
Published
2010-12-30
Epub
2010-00-30
Pages
126-63
Language
English
Region
Switzerland
NLM ID
101526829
PMCID
PMC3756353
External Links
PubMed source DOI: 10.3390/cancers3010126 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2